ProFibrix BV, a Leiden-based biotech company focused on products to stop bleeding and initiate tissue repair, has closed a Series A financing round raising $11m. The round was led by Index Ventures and backed by some of the current share holders of ProFibrix. It was also announced that Dr. Bram Bout, who previously held the position of VP protein production at Crucell and has approximately 15 years experience in the biopharmaceutical industry, has joined ProFibrix as of 1 April 2007 as chief technology officer.
This is the first divestment made by Nazca IV, a €275m vehicle raised by the GP in 2016
With the latest acquisition, IT Relation will add cybersecurity as its fourth business area, alongside cloud services, business consultancy and professional services
Industrial energy efficiency equipment producer sold its Poland-based operations in April 2020
Horizon bought a majority stake in Timico in 2016 via a deal valuing the company at more than £50m